June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Intraocular leukocyte response after IL-23 intravitreal injection as measured by intravital microscopy
Author Affiliations & Notes
  • Hyun Woong Kim
    ophthalmology, Busan Paik Hospital, Inje University, Busan, Republic of Korea
  • Christina Metea
    Casey Eye Institute, Oregon Health & Science University, Portland, OR
  • Stephen Planck
    Casey Eye Institute, Oregon Health & Science University, Portland, OR
  • James Rosenbaum
    Casey Eye Institute, Oregon Health & Science University, Portland, OR
    Devers Eye Institute, portland, OR
  • Footnotes
    Commercial Relationships Hyun Woong Kim, None; Christina Metea, None; Stephen Planck, None; James Rosenbaum, Genentech (C), Abbott (F), Xoma (C), Eyegate (F), Bristol Myers (F), Lux (C), Novartis (C), Regeneron (C), Teva (C), Therakine (F), Mitotech (F), Aquinox (F), Allergan (C), Santen (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2519. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hyun Woong Kim, Christina Metea, Stephen Planck, James Rosenbaum; Intraocular leukocyte response after IL-23 intravitreal injection as measured by intravital microscopy. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2519.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Uveitis is frequently associated with spondyloarthritis. Innate lymphoid cells that express the receptor for interleukin-23 (IL-23) have been recently implicated in the pathogenesis of ankylosing spondylitis (Sherlock et.al., Nature Medicine, 2012). However, it is unclear whether IL-23 plays a major role in the intraocular inflammation characteristic of spondyloarthropathies. We examined the leukocyte response within the eyes of mice after intravitreal injections of IL-23.

Methods: We injected IL-23 (100 ng/2 µl) into the vitreous of the right eye of BALB/c mice. Using intravital microscopy. we observed the leukocyte responses in the iris vessels at 6 hours (n=10) and at 24 hours (n=7) after IL-23 injection. We also injected different concentration of IL-23, 1 µg/2 µl (n=5) and monitored the same response at 3 hours and 6 hours after the injection

Results: Intravital microscopy revealed slow blood flow of iris vessels in 4 out of 10 mice at 6 hours and in 3 out of 7 mice at 24 hours in the IL-23 100 ng group. The average number of rolling leukocytes was 1803/min/mm2 at 6 hours and 1600/min/mm2 at 24 hours in the 100 ng group, compared with 1310/min/mm2 at 6 hours and 750/min/mm2 at 24 hours in the contralateral, saline-injected control eye. Leukocyte rolling was significantly increased at 24 hours after 100 ng of intravitreal IL-23 (p<0.05), but rolling was not significantly increased at other time points or after other concentrations of IL-23.The average number of sticking leukocytes was 91.7/mm2 at 6 hours and 108/mm2 at 24 hours in the 100 ng group, compared with 80.5/mm2 at 6 hours and 75.2/mm2 at 24 hours in the contralateral control eye. The average number of extravasated infiltrating leukocytes was 199/mm2 at 6 hours and 133/mm2 at 24 hours in the 100 ng group, compared with 141/mm2 at 6 hours and 129/mm2 at 24 hours in the contralateral control eye. Leukocyte sticking and infiltrating were not significantly increased at 6 hours and 24 hours after 100 ng of intravitreal IL-23 (p>0.05) and at other concentrations of IL-23.

Conclusions: Our data show blood flow changes and a transient increase in rolling leukocytes in iris vessels after IL-23 intravitreal injection. Further studies for the presence of resident CD3+, IL23R+ cells within eye will be informative with regard to the role of IL-23 in the uveitis.

Keywords: 432 autoimmune disease • 746 uveitis-clinical/animal model • 551 imaging/image analysis: non-clinical  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×